Skip to content

Category: Conference

Digital PATH Project looks to the future of oncology

Artificial intelligence algorithms are being integrated into various aspects of cancer research and care, including applications in pathology and diagnostic testing. Digital and computational pathology platforms have the potential to provide more precise and novel diagnostic insights to inform treatment decision making and, ultimately, improve patient outcomes. Friends of Cancer Research (Friends) is leading a…

Critical Findings from Friends HRD Harmonization Project

Homologous Recombination Deficiency (HRD) is a complex biomarker that can help identify patients likely to respond to certain therapies. Friends of Cancer Research’s (Friends) HRD Harmonization Project Harmonization Project is a unique research partnership to find alignment among different assays that measure HRD, to support its use as a biomarker in clinical research and care, and to serve as a foundational…

Watch Now: Friends of Cancer Research Annual Meeting 2023

On November 14, 2023, Friends of Cancer Research hosted our 16th Annual Meeting in Washington, D.C. Discussions at the meeting were the culmination of three working groups led by the organization over the past year, which collaboratively proposed solutions for three key challenges in oncology drug development: dose-finding in early phase trials, incorporating pragmatic elements in clinical trials, and using data from academic-led studies for regulatory decision-making.

Watch Now: Future in Focus: Digital Pathology in Oncology Drug Development

On September 26th, Friends of Cancer Research hosted, “Future in Focus: Digital Pathology in Oncology Drug Development,” a virtual public meeting to discuss the opportunities, challenges, and promises of digital and computational pathology in oncology drug development.

Watch Now: Supporting the Use of RWD in Oncology Drug Development

On September 11, 2023 Friends of Cancer Research hosted a public meeting, “Supporting the Use of RWD in Oncology Drug Development”, in Washington, DC. The meeting included a presentation of findings from the Friends Real-world Response (rw-Response) Pilot and two panel discussions focused on the regulatory implications for use of RWD and RWE in oncology drug development.

Watch Now: Establishing Evidence – New Advancements Using ctDNA

On July 11, 2023, Friends of Cancer Research hosted, “Establishing Evidence: New Advancements Using ctDNA”, a public meeting in Washington DC. The meeting included data readouts for two initiatives: 1) the Baseline circulating tumor DNA (ctDNA) Project and 2) the ctMoniTR Step 2 Module 1 data.

Watch Now: The Next Generation of Cellular Therapies – A Blueprint to Accelerate Development

On Monday, May 22, Friends of Cancer Research (Friends) hosted a hybrid public meeting titled “The Next Generation of Cellular Therapies: A Blueprint to Accelerate Development.” This meeting built on Friends’ previous work on Cell & Gene Therapies and was the second of two meetings in 2023 to explore next steps in the field.

Watch Now: The Next Generation of Cellular Therapies – Opportunities to Accelerate Development

On Wednesday, March 8, Friends of Cancer Research (Friends) hosted a virtual meeting titled “The Next Generation of Cellular Therapies: Opportunities to Accelerate Development.” This meeting sets the stage for a meeting on May 22 in Washington DC by providing context around the current state of the science and progress in cell therapy development. These…

Watch Now: Friends of Cancer Research Annual Meeting 2022

On Thursday, November 17, Friends of Cancer Research (Friends) was proud to host our 15th Annual Meeting to address critical issues in the development of new oncology drugs. After our last two Annual Meetings were hosted virtually, we welcomed attendees back safely in-person and virtually. The entire event can be viewed here and a summary…

Watch Now: Expediting Drug Development – Use of ctDNA as an Early Endpoint

On Wednesday, July 20, Friends of Cancer Research (Friends) hosted a meeting titled “Expediting Drug Development: Use of ctDNA as an Early Endpoint.” Welcoming everyone, Jeff Allen, President & CEO of Friends, provided updates regarding Friends’ ctDNA for Monitoring Treatment Response (ctMoniTR) project , a unique collaboration exploring whether changes in ctDNA levels can indicate clinical…